Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$17.05 USD
-1.05 (-5.80%)
Updated Sep 17, 2025 04:00 PM ET
After-Market: $17.18 +0.13 (0.76%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
SRPT 17.05 -1.05(-5.80%)
Will SRPT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SRPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SRPT
Sarepta Sells Arrowhead Stake to Fund Milestone Payment
Sarepta Soars on Q2 Earnings & Sales Beat, Resumes Elevidys Deliveries
SRPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sarepta Therapeutics (SRPT) Reports Q2 Earnings: What Key Metrics Have to Say
Sarepta Therapeutics (SRPT) Tops Q2 Earnings and Revenue Estimates
Sarepta to Report Q2 Earnings: What's in Store for the Stock?
Other News for SRPT
Crossed Above 50 Day Moving Average appears for SRPT after 3.61% move
BMO Capital Remains a Hold on Sarepta Therapeutics (SRPT)
Is SRPT setting up for a drop? 50 Day Moving Average Resistance shows up after climbing 0.46%
Expert Outlook: Sarepta Therapeutics Through The Eyes Of 43 Analysts
Wall Street Analysts Are Bullish on Top Healthcare Picks